The meta-analysis of Gager et al. (1) confirmed the consistent efficacy of SGLT2 inhibitors on the composite HF outcome (i.e., a composite of HHF/CVM) in various HF subgroups defined by several important factors, such as baseline diabetes status, type of SGLT2 inhibitors, and baseline level of eGFR. This evidence concerns the gene SLC5A2 and diabetes mellitus.